| Name | Title | Contact Details |
|---|
BehaVR is a new kind of digital therapeutics company dedicated to tackling the epidemic of anxiety-related challenges and disorders, to help curb chronic disease at scale. Partnering with the country`s leading academic institutions, research institutes and pharmaceutical companies, we innovate at the intersection of behavioral science, virtual reality and community design to develop immersive, evidence-based experiences that change peoples` lives. With every program we create, we commit to give people agency over their own health, and generate value, change, and better clinical outcomes for all stakeholders in the healthcare system.
Fitness by Fronk is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
United Home Health Services has been serving the community for 22 years. Five dedicated women professionals, including three nurses, a social worker, and a psychiatrist, established UHHS in 1983. This group of professionals identified the need to make a
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
MacPractice is a Lincoln, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.